ERBB2 and neoplasm: ZW25 is an IgG1 bispecific, biparatopic antibody binding to the ECD II and ECD IV domain of HER2 and has greater antitumor activity than trastuzumab plus pertuzumab preclinically through multiple antitumor mechanisms such as sufficient saturation binding to tumor cells [50].